Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 2/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | KDM5A | P29375 | 1/20 | 0.56 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.54 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.52 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.52 |
| ▸ | SSTR4 | P31391 | 3/20 | 0.49 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31654067 | 1.00 | GRM5 (0.60) | GRM5KDM4EGAAKMT2AKDM5A | |
| SCHEMBL25053100 | 0.92 | GRM5 (0.63) | GRM5KDM4EGAAKMT2AKDM5A | |
| SCHEMBL30200058 | 0.89 | GRM5 (0.62) | GRM5KDM4EGAAKMT2AKDM5A | |
| SCHEMBL21324599 | 0.86 | USP30 (0.72) | GRM5KDM4EKDM5ANTRK1USP30 | |
| SCHEMBL8063384 | 0.83 | KDM5A (0.70) | GRM5KDM4EGAAKMT2AKDM5A | |
| SCHEMBL21722409 | 0.81 | HRH2 (0.58) | GRM5KDM4EGAAKDM5ASMYD3 | |
| SCHEMBL3462409 | 0.81 | HRH2 (0.58) | GRM5KDM4EGAAKDM5ASMYD3 | |
| SCHEMBL14067296 | 0.81 | GRM5 (0.60) | GRM5KDM4EGAAKMT2AKDM5A | |
| SCHEMBL2241357 | 0.81 | GRM5 (0.77) | GRM5KDM4EGAAKMT2ASMYD3 | |
| SCHEMBL20068949 | 0.81 | SSTR4 (0.51) | KMT2AKDM5ANTRK1SSTR4SSTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112533904-B | Melanocortin subtype-2 receptor (MC 2R) antagonists and uses thereof | 克林提克斯医药股份有限公司 | 2024-10-29 | — | — | CN | claimed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8318750-B2 | Organic compounds | NOVARTIS AG (NL) | 2012-11-27 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| US-8258141-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-09-04 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004212-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20120004247-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2012-01-05 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
| US-20100286126-A1 | Organic Compounds | NOVARTIS AG (CH) | 2010-11-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286126-A1 | Organic Compounds | CYP3A43, SLCO1B3, CYP2C19 | GRM5 4603/4885KDM4E 3873/4885GAA 916/4885 |
| US-20120004212-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | GRM5 4603/4885KDM4E 3873/4885GAA 916/4885 |
| US-20120004247-A1 | ORGANIC COMPOUNDS | CYP3A43, SLCO1B3, CYP2C19 | GRM5 4603/4885KDM4E 3873/4885GAA 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.